^
    Back
    Association details:
    Biomarker:IRF8 expression
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance

    Published date:
    04/29/2020
    Excerpt:
    Decreased expression of IRF8 positively associated with CRPC progression and ENZ resistance.
    DOI:
    10.1158/0008-5472.CAN-19-2549